Role of myeloperoxidase in atrial fibrillation and ischemic heart disease

Atrial fibrillation and ischemic heart disease are the key problems in cardiology. Despite of numerous clinical trials and researches underlying molecular biology remains uncertain. Atrial fibrillation and ischemic heart disease are often combined. During ischemic heart disease progression myocardia...

Full description

Saved in:
Bibliographic Details
Main Authors: G. F. Bunenkova, S. P. Salikova, V. B. Grinevich, E. S. Ivanyuk
Format: Article
Language:Russian
Published: ABV-press 2023-01-01
Series:Klinicist
Subjects:
Online Access:https://klinitsist.abvpress.ru/Klin/article/view/507
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849467046087098368
author G. F. Bunenkova
S. P. Salikova
V. B. Grinevich
E. S. Ivanyuk
author_facet G. F. Bunenkova
S. P. Salikova
V. B. Grinevich
E. S. Ivanyuk
author_sort G. F. Bunenkova
collection DOAJ
description Atrial fibrillation and ischemic heart disease are the key problems in cardiology. Despite of numerous clinical trials and researches underlying molecular biology remains uncertain. Atrial fibrillation and ischemic heart disease are often combined. During ischemic heart disease progression myocardial tissue structure are changing which lead to structural and electrophysiological remodeling and promote atrial fibrillation. It has been shown a crucial role of oxidative stress and chronic systemic inflammation in ischemic heart disease and atrial fibrillation. Myeloperoxidase (MPO) is one of marker of oxidative stress and inflammation that located in azurophilic granules of neutrophils and monocytes. There are a numerous articles showed a relation between MPO level and cardiovascular disease. MPO is a peroxidase enzyme that is important part of immune system. During disease MPO could facilitate chronic inflammation and local tissue damage through active oxygen forms. MPO releases after lysosome conjunction with phagosome. Oxygen reductase activity of MPO lead synthesis of hypochlorous acid that play role not only in organism protection from infection agents but in matrix transformation and fibrosis. It has been shown MPO can destabilize atherosclerotic plaque and modifies low- and high-density lipoproteins that promote atherosclerosis and ischemic heart diseaseу progression. This review summarizes current data about role of MPO in atrial fibrillation and ischemic heart disease pathogenesis.
format Article
id doaj-art-3a591a46c64c483dadcb6eace155b1cc
institution Kabale University
issn 1818-8338
language Russian
publishDate 2023-01-01
publisher ABV-press
record_format Article
series Klinicist
spelling doaj-art-3a591a46c64c483dadcb6eace155b1cc2025-08-20T03:39:14ZrusABV-pressKlinicist1818-83382023-01-01163182410.17650/1818-8338-2022-16-3-K664386Role of myeloperoxidase in atrial fibrillation and ischemic heart diseaseG. F. Bunenkova0S. P. Salikova1V. B. Grinevich2E. S. Ivanyuk3Military Medical Academy named after S. M. Kirov of the Russian Ministry of DefenseMilitary Medical Academy named after S. M. Kirov of the Russian Ministry of DefenseMilitary Medical Academy named after S. M. Kirov of the Russian Ministry of DefenseMilitary Medical Academy named after S. M. Kirov of the Russian Ministry of DefenseAtrial fibrillation and ischemic heart disease are the key problems in cardiology. Despite of numerous clinical trials and researches underlying molecular biology remains uncertain. Atrial fibrillation and ischemic heart disease are often combined. During ischemic heart disease progression myocardial tissue structure are changing which lead to structural and electrophysiological remodeling and promote atrial fibrillation. It has been shown a crucial role of oxidative stress and chronic systemic inflammation in ischemic heart disease and atrial fibrillation. Myeloperoxidase (MPO) is one of marker of oxidative stress and inflammation that located in azurophilic granules of neutrophils and monocytes. There are a numerous articles showed a relation between MPO level and cardiovascular disease. MPO is a peroxidase enzyme that is important part of immune system. During disease MPO could facilitate chronic inflammation and local tissue damage through active oxygen forms. MPO releases after lysosome conjunction with phagosome. Oxygen reductase activity of MPO lead synthesis of hypochlorous acid that play role not only in organism protection from infection agents but in matrix transformation and fibrosis. It has been shown MPO can destabilize atherosclerotic plaque and modifies low- and high-density lipoproteins that promote atherosclerosis and ischemic heart diseaseу progression. This review summarizes current data about role of MPO in atrial fibrillation and ischemic heart disease pathogenesis.https://klinitsist.abvpress.ru/Klin/article/view/507atrial fibrillationischemic heart diseaseatherosclerosismyeloperoxidaseoxidative stresschronic inflammationneutrophilshypochlorous acidmatrix metalloproteinasespathogenesis
spellingShingle G. F. Bunenkova
S. P. Salikova
V. B. Grinevich
E. S. Ivanyuk
Role of myeloperoxidase in atrial fibrillation and ischemic heart disease
Klinicist
atrial fibrillation
ischemic heart disease
atherosclerosis
myeloperoxidase
oxidative stress
chronic inflammation
neutrophils
hypochlorous acid
matrix metalloproteinases
pathogenesis
title Role of myeloperoxidase in atrial fibrillation and ischemic heart disease
title_full Role of myeloperoxidase in atrial fibrillation and ischemic heart disease
title_fullStr Role of myeloperoxidase in atrial fibrillation and ischemic heart disease
title_full_unstemmed Role of myeloperoxidase in atrial fibrillation and ischemic heart disease
title_short Role of myeloperoxidase in atrial fibrillation and ischemic heart disease
title_sort role of myeloperoxidase in atrial fibrillation and ischemic heart disease
topic atrial fibrillation
ischemic heart disease
atherosclerosis
myeloperoxidase
oxidative stress
chronic inflammation
neutrophils
hypochlorous acid
matrix metalloproteinases
pathogenesis
url https://klinitsist.abvpress.ru/Klin/article/view/507
work_keys_str_mv AT gfbunenkova roleofmyeloperoxidaseinatrialfibrillationandischemicheartdisease
AT spsalikova roleofmyeloperoxidaseinatrialfibrillationandischemicheartdisease
AT vbgrinevich roleofmyeloperoxidaseinatrialfibrillationandischemicheartdisease
AT esivanyuk roleofmyeloperoxidaseinatrialfibrillationandischemicheartdisease